Articles tagged "Safety"

2018 American Transplant Congress
Trends in Safety Reporting to UNOS by Event Type
A. Doyle,¹ S. Tlusty,² R. Urban,² M. Marvin,³ E. Hollinger,⁵ D. Marshman,⁴ M. Green.⁵
¹Medicine, University of Virginia, Charlottesville, VA; ²UNOS, Ichmond, VA; ³Surgery, Geisinger, Davville, PA; ⁴LifeLink Foundation, Norcross, GA; ⁵Surgery, University of Pittsbugh, Pittsburgh, PA; ⁶Surgery, Rush Medical Center, Chicago, IL.
The UNOS Operations and Safety Committee is charged with reviewing reported patient safety situations, identifying safety gaps, addressing high frequency and high impact events, and…
2018 American Transplant Congress
Outcomes of Retroperitoneoscopic Live Donor Nephrectomy (RPLDN): Experience of 1100 Cases at a Single Center
K. Omoto,^1,2 M. Okumi,¹ Y. Kakuta,¹ H. Noguchi,¹ K. Unagami,¹ M. Inui,¹ H. Ishida,¹ K. Tanabe.¹
¹Department of Urology, Tokyo Women's Medical University, Tokyo, Japan; ²Department of Transplant Surgery, Toda Chuo General Hospital, Toda, Japan.
INTRODUCTION: Laparoscopic donor nephrectomy is a standard method of donor nephrectomy. We have tried to establish the technique of pure retroperitoneoscopic live donor nephrectomy (RPLDN)…
2017 American Transplant Congress
Subclinical Rejections in Kidney Transplant Recipients Treated with Direct Acting Antiviral Agents for Hepatitis C Treatment within 1 Year of Transplant.
T. Rege,¹ K. Hatahet,¹ A. Gillespie,¹ M. Ghanta,¹ I. Lee,¹ K. Qureshi,¹ K. Lau,² S. Karhadkar,² A. DiCarlo,² S. Constantinescu,¹ S. Rao.¹
¹Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA; ²Surgery, Temple University, Philadelphia, PA
Direct acting antiviral agents (DAA) have revolutionized the management of Hepatitis C virus (HCV) positive kidney transplant recipients (KTR). The optimal timing of DAA therapy…
2017 American Transplant Congress
Improving Value by Standardizing the Use of IVIG Amongst Pediatric Solid Organ Transplant (SOT) Patients.
J. Sawyer,¹ J. Bucuvalas,² L. Danziger-Isakov,³ J. Gossett,³ L. Burkhart,³ A. Lorts.³
¹Division of Pharmacy, Cincinnati Children's Hospital Medical Center, Cincinnati; ²Division of Gastroenterology, Cincinnati Children's Hospital Medical Center, Cincinnati; ³Solid Organ Transplant Center, Cincinnati Children's Hospital Medical Center, Cincinnati
Background: Given the high cost of pharmaceuticals (i.e. IVIG), we sought to determine if unnecessary variation in drug use may be an opportunity to improve…
2017 American Transplant Congress
Safety of Liver Donation from Living Donors with Sickle Cell Trait.
H. Elsiesy,^1,2 M. Sturdevant,¹ W. Al-Hamoudi,¹ H. Elbeshbeshy,¹ M. Al Sebayel,¹ A. Jaafari,¹ F. Abaalkhail.^1,2
¹Liver Trasplantation, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; ²Medicine, Alfaisal University, Riyadh, Saudi Arabia; ³Gastroenterology, King Saud University, Riyadh, Saudi Arabia
Background:Living donor liver transplant (LDLT) is an important source of organs particularly with the cadaveric organ shortage. It is the main source of liver transplant…
2017 American Transplant Congress
Risk of Major Bleeding in Solid Organ Transplant Recipients Taking Calcineurin Inhibitors Concomitantly with Direct Oral Anticoagulants Compared to Warfarin.
J. Hazelcorn, R. Yau, N. Sabagha, M. Moaddab, M. Manson.
Pharmacy, CHI St. Luke's Health-Baylor St. Luke's Medical Center, Houston, TX
Purpose: Direct oral anticoagulants (DOAC) and calcineurin inhibitors (CNI) are both substrates of CYP 3A metabolism; therefore, the purpose of this study is to assess…
2017 American Transplant Congress
Safety of Percutaneous Pancreas Allograft Biopsy in Enteric Drained Pancreas Transplants.
Y. Kassis, E. Poggio, Z. Zaky.
Nephrology and Hypertension, Cleveland Clinic Foundation, Cleveland, OH
Background: Pancreas allograft biopsy (Bx) is the gold standard in diagnosing allograft rejection. The safety of this procedure has been controversial, thus limiting its widespread…
2017 American Transplant Congress
Confirmation of the Safety of Cryopreserved Human Cord Blood Derived Di-Chimeric Cells in the NSG Mouse Model.
J. Cwykiel, N. Filipek, E. Szilagyi, E. Tfaily, M. Siemionow.
Orthopaedics, University of Illinois at Chicago, Chicago, IL
Background: Cell therapies are a promising approach for tolerance induction in Vascularized Composite Allotransplantation (VCA). Thus, we have developed a new supportive therapy of ex…
2017 American Transplant Congress
Alloimmune Quiescence in Recipients with Long-Term Surviving Kidney Grafts.
K. Brown,¹ W. Baldwin,¹ E. Poggio,² W. Braun,² R. Fairchild.¹
¹Department of Immunology, Cleveland Clinic, Cleveland, OH; ²Nephrology and Glickman Urological Institue, Cleveland Clinic, Cleveland, OH
Recent studies of tolerant kidney transplant patients have identified increased numbers of circulating B cells expressing an immature/transitional phenotype (IgD+CD27-/IgD+CD27-CD24+CD38+). Similar frequencies of these immature/transitional…
2017 American Transplant Congress
Efficacy and Safety of Everolimus with Reduced Tacrolimus or Cyclosporine in Pediatric Liver Transplant Recipients: 12-Month Results from H2305 Study.
A. Weymann,¹ R. Ganschow,¹ B. Ericzon,¹ A. Dhawan,¹ K. Sharif,¹ E.-D. Martzloff,² B. Rauer,² J. Ng,² P. Lopez.²
¹H2305 Study Group, St Louis; ²Novartis Pharma AG, Basel, Switzerland
Purpose: Everolimus (EVR) facilitated calcineurin inhibitor (CNI) reduction has shown improved renal function (RF) without compromising efficacy in adult liver transplant recipients (LTxR). Here we…